Yeast-based Identification of Prostate Tumor Antigens Provides an Effective Vaccine Platform

To evaluate cancer/testis (CT) antigens as targets for immunotherapy or vaccine approaches in prostate cancer. We investigated the antibody response in 181 patients with prostate cancer, 83 benign prostate hyperplasia (BPH) patients, and 39 healthy donors against 13 different CT antigens recombinant...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2010-03, Vol.30 (3), p.895-902
Main Authors: JUNG, Volker, FISCHER, Eliane, WADLE, Andreas, IMIG, Jochen, KLEBER, Sascha, NUBER, Natko, REINSHAGEN, Frank, KAMRADT, Jorn, GROBHOLZ, Rainer, KNUTH, Alexander, RENNER, Christoph
Format: Article
Language:English
Subjects:
Antigen-Presenting Cells - immunology
Antigens, Neoplasm - biosynthesis
Antigens, Neoplasm - immunology
Antigens, Surface - immunology
Biological and medical sciences
Cancer Vaccines - immunology
Dendritic Cells - immunology
Humans
Immunohistochemistry
Male
Medical sciences
Membrane Proteins - biosynthesis
Membrane Proteins - immunology
Neoplasm Proteins - immunology
Nephrology. Urinary tract diseases
Prostatic Hyperplasia - blood
Prostatic Hyperplasia - immunology
Prostatic Neoplasms - blood
Prostatic Neoplasms - immunology
Repressor Proteins - immunology
T-Lymphocytes, Cytotoxic - immunology
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Yeasts - immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate cancer/testis (CT) antigens as targets for immunotherapy or vaccine approaches in prostate cancer. We investigated the antibody response in 181 patients with prostate cancer, 83 benign prostate hyperplasia (BPH) patients, and 39 healthy donors against 13 different CT antigens recombinantly expressed on yeast surface (RAYS) and compared the results to antigen expression in tumor tissue. We then used the yeast clone expressing the most promising antigen directly as a vaccine to elicit potent cellular immunity. The antibody response to NY-ESO-1 was more frequent (20%) and strong compared to other investigated antigens, and was associated with progressive disease. Interestingly, it was also detected in several BPH patients (9%). Feeding dendritic cells with NY-ESO-1-expressing yeast cells resulted in efficient HLA presentation and activation of specific CD3(+) T-cells. The RAYS approach offers a fast means of analyzing serological autoreacitvity in cancer patients and serves as an effective anticancer vaccine platform.
ISSN:0250-7005
1791-7530